<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131544</url>
  </required_header>
  <id_info>
    <org_study_id>Prostate Laser Center BPH 01</org_study_id>
    <nct_id>NCT03131544</nct_id>
  </id_info>
  <brief_title>MRI Guided Transrectal Prostate Laser Ablation for Benign Prosatic Hypertrophy (BPH)</brief_title>
  <official_title>MRI Guided Transrectal Prostate Laser Ablation for Benign Prosatic Hypertrophy (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostate Laser Center, PLLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic, Inc., a Minnesota, U.S.A. company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prostate Laser Center, PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to
      evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm
      laser (VisualaseTM by Medtronic, Inc., a Minnesota, U.S.A. company) to treat benign prostatic
      hypertrophy (BPH). The laser system will be used to necrotize urological soft tissue within
      the prostate under MRI guidance. This will be a single center, single arm prospective trial
      with an anticipated enrollment of 10 men. Patients who elect this treatment option and choose
      to be part of the study will be enrolled consecutively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS) Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Symptom Score Quality of Life Question Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BPH Impact Index Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Health Inventory of Men (SHIM) Score Change</measure>
    <time_frame>Time Frame: Baseline, 2 months, 4 months, 6 months and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Continuous until completion of the study at 2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>BPH</condition>
  <condition>Prostate Hyperplasia</condition>
  <condition>Urinary Frequency/Urgency</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI Guided Transrectal Periuretheral Transitional Zone Ablation</intervention_name>
    <description>Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.</description>
    <other_name>Visualase</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men above the age of 45 with benign prostatic hypertrophy (BPH) with lower urinary tract
        symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of lower urinary track symptoms (LUTS).

          2. Prostate volume of 40 - 200 cc.

          3. Men ≥ 45 years old.

          4. IPSS ≥ 15.

          5. BPH Impact Index ≥ 5.

        Exclusion Criteria:

          1. History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, or
             findings suggestive of likely underlying prostate cancer.

          2. Need to catheterize to relieve obstruction.

          3. Daily use of incontinence materials/padding.

          4. Neurogenic or hypotonic bladder, Parkinson's Disease, or a history of uncontrolled
             diabetes.

          5. Prior interventional or surgical treatment of BPH.

          6. Penile prosthesis.

          7. Artificial urinary sphincter or collagen bladder injection.

          8. Urethral stricture.

          9. Bleeding disorder/coagulopathy.

         10. Inability to refrain from blood thinners in the peri-procedural period.

         11. Inability or chooses not to provide informed consent.

         12. Any serious medical condition which would make proceeding to treatment unsafe.

         13. Significant contraindication to MRI or gadolinium contrast.

         14. Hip replacement.

         15. Lack of a rectum.

         16. Life expectancy of less than two years.

         17. Unable or unwilling to complete all required questionnaires and follow-up assessments.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prostate Laser Center, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ara Karamanian, MD</last_name>
      <phone>713-904-4014</phone>
      <email>ClinicalTrials@ProstateLaserCenter.com</email>
    </contact>
    <investigator>
      <last_name>Ara Karamanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ProstateLaserCenter.com/</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>Benign Prostatic Hypertrophy</keyword>
  <keyword>MRI</keyword>
  <keyword>Prostate</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <keyword>Nocturia</keyword>
  <keyword>Incomplete bladder emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

